Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) related to its sale to Indivior Pharmaceuticals, Inc. Under the terms of the proposed transaction, Supernus shareholders are expected to receive 1.5401 common shares of Indivior for each share of Supernus.